In this podcast, Joohi Jimenez-Shahed, MD, discusses the findings of the study, “Safety, Tolerability, and Pharmacodynamic Profile of DNL201 at dose levels demonstrating LRRK2 inhibition in Parkinson's Disease Patients with and without LRRK2 mutations,” which was presented at the International Parkinson and Movement Disorder Society Virtual Congress.
Early findings presented at the International Parkinson and Movement Disorders 2020 Virtual Congress indicate that an α-synuclein active immunotherapeutic drug appears to be safe and well-tolerated, and generated a substantial humoral immune response with target engagement, among patients with Parkinson disease. Neurology Learning Network discussed these findings further with Joohi Jimenez-Shahed, MD.
This news roundup features new findings presented at the MDS Virtual 2020 Congress, including the key role loneliness may play in Parkinson disease (PD) severity, as well as superiority data on directional vs omnidirectional deep brain stimulation in PD.